Evaluation of the Safety and Effectiveness of Two Nomograms for the Management of Diabetic Ketoacidosis

评估两种用于管理糖尿病酮症酸中毒的列线图的安全性和有效性

阅读:1

Abstract

BACKGROUND: No standardized nomogram has been established to reduce hypoglycemia events while optimizing clinical outcomes for patients with diabetic ketoacidosis (DKA). OBJECTIVE: To evaluate the safety and effectiveness of two DKA nomograms. METHODS: We conducted a multicenter, retrospective cohort study in adult patients (≥18 years) treated with IV insulin for DKA. Cohorts were categorized based on the insulin nomogram utilized: Standard Incremental Nomogram with Glucose-Level Evaluation (SINGLE) and Multiple Algorithm Nomogram using Insulin Change and Rate Estimate (MULTIPLE). Patients were excluded if they were experiencing pregnancy, euglycemic DKA, or hyperosmolar hyperglycemic state. The primary outcome was hypoglycemic events (BG < 70 mg/dL). Secondary outcomes included time to DKA resolution and DKA recurrence. RESULTS: A total of 234 patients were included (SINGLE n = 117, MULTIPLE n = 117). Hypoglycemia occurred in eight patients in the MULTIPLE group (6.8%) versus 25 patients in the SINGLE group (21.4%) (P< 0.01) after controlling for confounders, hypoglycemia remained highest in the SINGLE cohort versus the MULTIPLE cohort (OR 3.0 [95% CI 1.2-7.2], P < 0.01). After controlling for confounders, hypoglycemia remained highest in the SINGLE cohort versus the MULTIPLE cohort (OR 3.0 [95% CI 1.2-7.2], P < 0.01). Significant differences were not observed between the two nomograms in time to DKA resolution (16.4 hours [IQR 10.2-28.3] vs 16.1 [IQR 10.0-22.8], P = 0.19), recurrence rates (11.1% vs 15.4%, P = 0.34) or ICU LOS (P = 0.06). CONCLUSION: The MULTIPLE nomogram had fewer hypoglycemia events with no difference in time to DKA resolution. Additional studies are needed to evaluate varying nomograms to determine the optimal approach.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。